CCR5 Δ32 polymorphism: Associated with gallbladder cancer susceptibility

Scandinavian Journal of Immunology

Volumn 67, Issue 5, 2008, Pages 516-522

  Srivastava, A ^a   Pandey, S N ^a   Choudhuri, G ^a   Mittal, B ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5;

ADULT; AGED; ALLELE; ARTICLE; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; FEMALE; GALLBLADDER CANCER; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; TOBACCO; CANCER STAGING; CASE CONTROL STUDY; GALLBLADDER TUMOR; GALLSTONE; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; INDIA; MIDDLE AGED; PATHOLOGY; SMOKING;

ALLELES; CASE-CONTROL STUDIES; FEMALE; GALLBLADDER NEOPLASMS; GALLSTONES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INDIA; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RECEPTORS, CCR5; RISK FACTORS; SMOKING;

EID: 42049112225     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2008.02097.x     Document Type: Article

References (38)

1. Wistuba I, Ashfaq R, Maitra A, Alvarez H, Riquelme E, Gazdar AF. Fragile histidine triad gene abnormalities in the pathogenesis of gallbladder carcinoma. Am J Pathol 2002 60 : 2073 9.
2. Indian Council of Medical Research (ICMR). Annual Report of Population Based Cancer Registries of the National Cancer Registry Programme 1993. New Delhi : ICMR Publication, Vol. 18, 1996.
3. Mishra S, Chaturvedi A, Misra NC, Sharma ID. Carcinoma of the gallbladder. Lancet Oncol 2003 4 : 167 76.
4. Coleman MP, Esteve J, Damiecki P, Arslan A, Renard H. Trends in Cancer Incidence and Mortality. Lyon : IARC, 1993.
5. Lazcano-Ponce EC, Miquel JF, Munoz N. Epidemiology and molecular pathology of gallbladder cancer. CA Cancer J Clin 2001 51 : 349 64.
6. Wistuba II., Gazdar AF. Gallbladder cancer: lessons from a rare tumor. Nat. Rev Cancer 2004 4 : 695 706.
7. Fraumeni JF Jr. Cancers of the pancreas and biliary tract: epidemiological considerations. Cancer Res 1975 35 : 3437 46.
8. Kimura W, Shimada H, Kuroda A, Morioka Y. Carcinoma of gallbladder and extra hepatic bile duct in autopsy case of the aged, with special reference to its relationship to gallstone. Am J Gastroenterol 1989 84 : 386 90.
9. Takahashi T, Shivapurkar N, Riquelme E et al. Aberrant promoter hypermethylation of multiple genes in gallbladder carcinoma and chronic cholecystitis. Clin Cancer Res 2004 10 : 6126 33.
10. Albores-Saavedra J, Alcantra-Vazquez A, Cruz-Ortiz H, Herrera-Goepfert R. The precursor lesions, of invasive gallbladder carcinoma, hyperplasia, atypical hyperplasia and carcinoma in situ. Cancer 1980 45 : 919 27.
11. Jiao XY, Lü MD, Huang JF, Liang LJ, Shi JS. Genomic determination of CR1, CD35 density polymorphism on erythrocytes of patients with gallbladder carcinoma. World J Gastroenterol 2004 10 : 3480 4.
12. Duell EJ, Casella DP, Burk RD, Kelsey KT, Elizabeth A. Holly inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2006 15 : 726 31.
13. Horuk R. Molecular properties of the chemokines receptor family. Trends Pharmacol Sci 1994 15 : 159 65.
14. Rüster M, Sperschneider H, Fünfstück R, Stein G, Gröne HJ. Differential expression of beta-chemokines MCP-1 and RANTES and their receptors CCR1, CCR2, CCR5 in acute rejection and chronic allograft nephropathy of human renal allografts. Clin Nephrol 2004 61 : 30 9.
15. Savard CE, Blinman TA, Choi HS, Lee SK, Pandol SJ, Lee SP. Expression of cytokine and chemokine mRNA and secretion of tumor necrosis factor-alpha by gallbladder epithelial cells: response to bacterial lipopolysaccharides. BMC Gastroenterol 2002 2 : 23.
16. Mummidi S, Ahuja SS, McDaniel BL, Ahuja SK. The human CC chemokine receptor 5 (CCR5) gene. J Biol Chem 1997 272 : 30662 71.
17. Paterlini MG. Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity. Biophys J 2002 83 : 3012 31.
18. Liu R, Paxton WA, Choe S et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 Infection. Cell 1996 86 : 367 77.
19. Degerli N, Yilmaz E, Bardakci F. The Δ32 allele distribution of the CCR5 gene and its relationship with certain cancers in a Turkish population. Clin Biochem 2005 38 : 248 52.
20. Bearhs O, Henson D, Hutter R. Manual for Staging of Cancer. Philadelphia, PA : Lippincott, 1988.
21. Miller SA, Dykes DD, Polesky HF. A salting procedure for extracting DNA from nucleated cells. Nucleic Acid Res 1988 16 : 1215.
22. Munerato P, Azevedo ML, Sucupira MCA et al. Frequency of polymorphisms of genes coding for HIV-1 co-receptors CCR5 and CCR2 in a Brazilian population. Braz J Infect Dis 2003 7 : 236 40.
23. Dewin DR, Catusse J, Gompels UA. Identification and characterization of U83A viral chemokine, a broad and potent β chemokine agonist for human CCR's with unique selectivity and inhibition by spliced isoform. J Immunol 2005 176 : 544 56.
24. Luboshits G, Shina S, Kaplan O et al. Elevated expression of the CC chemokines regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res 1999 59 : 4681 7.
25. Negus RPM, Stamp GWH, Hadley J, Balkwill FR. A quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am J Pathol 1997 150 : 1723 34.
26. Zheng B, Wiklund F, Gharizadeh B et al. Genetic polymorphism of chemokine receptors CCR2 and CCR5 in Swedish cervical cancer patients. Anticancer Res 2006 26 : 3669 74.
27. Vaday GG, Peehl DM, Kadam PA, Lawrence PA. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 2006 66 : 124 34.
28. Martinson JJ, Chapman NH, Rees DC, Liu YT, Clegg JB. Global distribution of the CCR5 gene 32-basepair deletion. Nat Genet 1997 16 : 100 3.
29. Samson M, Libert F, Doranz BJ et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996 382 : 722 5.
30. Libert F, Cochaux P, Beckman G et al. The delta CCR5 mutation conferring protection against HIV-1 in Caucasian populations has a single and recent origin in North Eastern Europe. Hum Mol Genet 1998 7 : 399 406.
31. Lu Y, Nerurkar VR, Dashwood WM et al. Genotype and allele frequency of a 32-base pair deletion mutation in the CCR5 gene in various ethnic groups: Absence of mutation among Asians and Pacific Islanders. Int J Infect Dis 1993 3 : 186 91.
32. Sharda S, Gilmour A, Harris V et al. Chemokine receptor 5 (CCR5) deletion polymorphism in North Indian patients with coronary artery disease. Int J Cardiol 2007 124 : 254 8.
33. Trecarichi EM, Tumbarello M, Donati KG et al. Partial protective effect of CCR5-Delta 32 heterozygosity in a cohort of heterosexual Italian HIV-1 exposed uninfected individuals. AIDS Res Ther 2006 3 : 22.
34. Zafiropoulos A, Crikas N, Passam AM, Spandidos DA. Significant involvement of CCR2-64I and CXCL12-3a in the development of sporadic breast cancer. J Med Genet 2004 41 : e59.
35. Bartek J, Iggo R, Gannon J, Lane DP. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990 5 : 893 9.
36. Manes S, Mira E, Colomer R et al. CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med 2003 198 : 1381 9.
37. Rodrigues NR, Rowan A, Smith MEF et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci 1990 87 : 7555 9.
38. Azenshtein E, Luboshits G, Shina S et al. The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity. Cancer Res 2002 62 : 1093 102.